Global Endometrial Cancer Market Size (2024 - 2029)

The endometrial cancer treatment market is projected to experience growth, driven by an increase in the incidence of cases, heightened healthcare expenditure, and advancements in diagnostic and treatment technologies. The market's expansion is further supported by rising awareness initiatives and collaborations aimed at educating the public about endometrial cancer. However, challenges such as the high cost of treatment, adverse effects, and drug toxicity may impede market growth. The COVID-19 pandemic initially disrupted diagnostic activities, but the market is expected to recover and grow post-pandemic.

Market Size of Global Endometrial Cancer Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Endometrial Cancer Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
CAGR 4.90 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Endometrial Cancer Market Major Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Endometrial Cancer Market Analysis

The endometrial cancer market is expected to register a CAGR of 4.9% during the forecast period.

The COVID-19 pandemic had a moderate impact on the endometrial cancer market due to the reduction in patient visits for diagnosis during the initial phases of the COVID-19 pandemic. As per a study published in January 2022 in PubMed, the corona outbreak correlated with the disruption of screening activities and diagnostic assessments.

Endometrial cancer (EC) is one of the most common gynecological malignancies, and it is often detected at an early stage because it frequently produces symptoms. The data suggested that the COVID-19 pandemic had a significant impact on the characteristics and patterns of care of EC patients. However, post-pandemic, the market is anticipated to witness growth due to a rise in the incidence of endometrial cancer cases, an increase in healthcare expenditure, and technological advancements in endometrial cancer diagnosis and treatment.

For instance, as per a September 2022 update from Cancer Australia, an estimated 3,343 new cases of uterine cancer were diagnosed in Australia in 2022. Similarly, as per a Canadian Cancer Society May 2022 update, an estimated 8,100 Canadian women were likely to be diagnosed with uterine cancer in 2022. As per a May 2021 update from the Mayo Clinic, endometrial cancer begins in the layer of cells that form the lining (endometrium) of the uterus. Endometrial cancer is sometimes called uterine cancer.

Moreover, the rise in awareness programs and collaboration relating to endometrial cancer is anticipated to boost market growth. For instance, in March 2021, Eisai Inc. launched an initiative called 'Spot Her' to end the silence around endometrial cancer and inspire women to listen, advocate, and put their health and the health of other women first. The initiative was conducted in partnership with SHARE Cancer Support (SHARE), Facing Our Risk of Cancer Empowered (FORCE), and Black Health Matters. Moreover, in November 2021, the UNC Lineberger Comprehensive Cancer Center launched the Endometrial Cancer Center of Excellence to advance the scientific understanding of the causes, prevention, and clinical treatment of endometrial cancer and aid researchers in discovering the underlying factors that contribute to why black women in North Carolina are twice as likely to die from endometrial cancer. Such developments spread awareness about endometrial cancer, thereby boosting the demand for the endometrial cancer treatment market.

Factors, such as those mentioned above play a big role in boosting the market growth. But, the high cost associated with the treatment, the adverse effects of the treatment, and the high toxicity of drugs can be a hindrance.

Endometrial Cancer Industry Segmentation

As per the scope of this report, endometrial cancer is a malignancy that develops in the layers of the cells that form the endometrium, the lining of the uterus. Women with high blood pressure, diabetes, or breast cancer are at a greater risk of getting endometrial cancer. 

The endometrial cancer market is segmented by Type of Cancer (Endometrial Carcinoma (Adenocarcinoma, Carcinosarcoma, Squamous Cell Carcinoma, Other Types of Cancer), Uterine Sarcomas), Type of Therapy (Immunotherapy, Radiation Therapy, Chemotherapy, and Other Types of Therapies), Diagnosis Method (Biopsy, Pelvic Ultrasound, Hysteroscopy, CT Scan, and Other Diagnosis Methods), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the market sizes and forecasts in terms of value (USD million) for the above segments.

By Type of Cancer
Endometrial Carcinoma
Adenocarcinoma
Carcinosarcoma
Squamous Cell Carcinoma
Other Types of Cancer
Uterine Sarcomas
By Type of Therapy
Immunotherapy
Radiation Therapy
Chemotherapy
Other Types of Therapies
By Diagnosis Method
Biopsy
Pelvic Ultrasound
Hysteroscopy
CT Scan
Other Diagnosis Methods
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Global Endometrial Cancer Market Size Summary

The endometrial cancer treatment market is poised for growth, driven by an increasing incidence of endometrial cancer cases and advancements in diagnostic and therapeutic technologies. The market experienced a moderate impact due to the COVID-19 pandemic, which disrupted screening and diagnostic activities, but is expected to recover and expand as healthcare expenditure rises and awareness programs gain traction. Initiatives like Eisai Inc.'s 'Spot Her' and the UNC Lineberger Comprehensive Cancer Center's efforts to understand endometrial cancer disparities are contributing to heightened awareness and demand for treatment. Despite challenges such as high treatment costs and drug toxicity, the market is supported by the growing prevalence of endometrial cancer and the development of new chemotherapy products, which are integral to post-surgical treatment regimens.

North America is anticipated to be a significant growth region for the endometrial cancer market, bolstered by a well-developed healthcare infrastructure and increased cancer diagnosis awareness. The region hosts numerous clinical studies and strategic initiatives by key market players, such as Karyopharm Therapeutics and Sysmex Corporation, which are advancing treatment options and expanding market offerings. The competitive landscape includes major companies like Bristol-Myers Squibb, Pfizer, and Siemens Healthineers, with ongoing trials and product developments expected to attract new entrants. Regulatory approvals, such as the FDA's endorsement of Merck's KEYTRUDA for advanced endometrial carcinoma, further underscore the market's potential for expansion and innovation.

Explore More

Global Endometrial Cancer Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Rising Awareness about Uterine Diseases and Available Therapies

      2. 1.2.2 Increase in Prevalence of Endometrial Cancer Cases

      3. 1.2.3 Innovation in Drug Development and Subsequent Technological Advancements

    3. 1.3 Market Restraints

      1. 1.3.1 High Cost Associated with the Treatment

      2. 1.3.2 Adverse Effects of the Treatment and High Toxicity of Drugs

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Bargaining Power of Suppliers

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 2.1 By Type of Cancer

      1. 2.1.1 Endometrial Carcinoma

        1. 2.1.1.1 Adenocarcinoma

        2. 2.1.1.2 Carcinosarcoma

        3. 2.1.1.3 Squamous Cell Carcinoma

        4. 2.1.1.4 Other Types of Cancer

      2. 2.1.2 Uterine Sarcomas

    2. 2.2 By Type of Therapy

      1. 2.2.1 Immunotherapy

      2. 2.2.2 Radiation Therapy

      3. 2.2.3 Chemotherapy

      4. 2.2.4 Other Types of Therapies

    3. 2.3 By Diagnosis Method

      1. 2.3.1 Biopsy

      2. 2.3.2 Pelvic Ultrasound

      3. 2.3.3 Hysteroscopy

      4. 2.3.4 CT Scan

      5. 2.3.5 Other Diagnosis Methods

    4. 2.4 Geography

      1. 2.4.1 North America

        1. 2.4.1.1 United States

        2. 2.4.1.2 Canada

        3. 2.4.1.3 Mexico

      2. 2.4.2 Europe

        1. 2.4.2.1 Germany

        2. 2.4.2.2 United Kingdom

        3. 2.4.2.3 France

        4. 2.4.2.4 Italy

        5. 2.4.2.5 Spain

        6. 2.4.2.6 Rest of Europe

      3. 2.4.3 Asia-Pacific

        1. 2.4.3.1 China

        2. 2.4.3.2 Japan

        3. 2.4.3.3 India

        4. 2.4.3.4 Australia

        5. 2.4.3.5 South Korea

        6. 2.4.3.6 Rest of Asia-Pacific

      4. 2.4.4 Middle East and Africa

        1. 2.4.4.1 GCC

        2. 2.4.4.2 South Africa

        3. 2.4.4.3 Rest of Middle East and Africa

      5. 2.4.5 South America

        1. 2.4.5.1 Brazil

        2. 2.4.5.2 Argentina

        3. 2.4.5.3 Rest of South America

Global Endometrial Cancer Market Size FAQs

The Global Endometrial Cancer Market is projected to register a CAGR of 4.90% during the forecast period (2024-2029)

Elekta AB, Karyopharm Therapeutics, Eisai Co., Ltd., GSK plc and Siemens Healthineers (Varian Medical Systems, Inc.) are the major companies operating in the Global Endometrial Cancer Market.

Endometrial Cancer Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)